News | Peripheral Artery Disease (PAD) | October 01, 2015

FDA OKs Intact Vascular Trial for Tack Optimized Balloon Angioplasty II Study

TOBA II Study designed to demonstrate enhanced dissection repair following balloon angioplasty

Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

October 1, 2015 — Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and European investigational device exemption (IDE) clinical trial of the Tack Endovascular System. The device will be investigated for use as a dissection repair therapy in patients with peripheral arterial disease (PAD) undergoing percutaneous angioplasty. The Tack Optimized Balloon Angioplasty II (TOBA II) trial has begun, with the first patients being treated at Yuma Regional Medical Center in Yuma, Arizona.

William A. Gray, M.D., director of endovascular services at Columbia University Hospital, is providing study leadership as the national principal investigator.

The TOBA II study is designed to enroll 210 subjects at 30-40 sites in the United States and Europe. All study subjects need to be suffering from advanced PAD in one or both legs. They will be treated with the Tack Endovascular System following standard balloon angioplasty or drug-coated balloon angioplasty in the superficial femoral and proximal popliteal arteries when a dissection (a tear in the artery wall) occurs.

The Tack Endovascular System is a new technology designed to repair dissections that frequently occur as a complication of balloon angioplasty. Published literature reports up to 88 percent of angioplasty procedures have dissections. Earlier this year, promising 12-month results from the company’s European TOBA study were presented at a major vascular conference in Germany and demonstrated the potential of the Tack implant for improving arterial healing following angioplasty. Most importantly, the system allows physicians to repair dissections while leaving a minimal amount of foreign material in the artery, reducing mechanical stress on the artery and preserving future treatment options.

Gray stated, “The earlier TOBA experience demonstrates that the long term results from angioplasty can be substantially improved if we repair arterial dissections using this new approach to minimize vessel trauma while leaving as little metal behind as possible. The Tack implant supports the dissection and allows the vessel to heal, while preserving future treatment options for patients. I am very excited that the TOBA II trial will allow us to study this technology in combination with both standard and drug-coated angioplasty balloons – a first of its kind study design. No other vascular implants have been methodically studied following vessel treatment with a drug-coated balloon.”

The first patients in the TOBA II trial were enrolled by Joseph Cardenas, M.D. at Yuma Regional Medical Center. Cardenas said, “This new approach of spot treating dissections supports our desire to leave as little metal behind as possible. The Tack implant is also uniquely designed to adapt to the diameter of the vessel in which it is implanted, unlike stents, which have to be specifically sized to the vessel. This makes the procedure fast, flexible and user-friendly for the hospital staff and the operator to efficiently treat our patients.”

For more information:

Related Content

American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018
March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help impro
Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init